Clareo Health | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age
Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma
Completion of only one previous course of chemotherapy which contained a platinum therapy, with resistance to that regimen. "Platinum-resistance" is defined by a relapse within 2 to 6 months after termination of platinum-based chemotherapy
Measurable disease, defined by at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded), and is ≥ 20 mm when measured by conventional techniques (palpation, plain x-ray, computed tomography \[CT\], or magnetic resonance imaging \[MRI\]) or ≥ 10 mm when measured by spiral CT
Adequate organ function defined as: absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets ≥ 100,000/mm3, creatinine clearance \> 50mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x upper limit of normal (ULN; or \< 5 x ULN in case of liver metastases); total bilirubin \< 1.5 mg/dL
For women of child bearing potential, documented negative pregnancy test within two weeks of study entry and agreement to acceptable birth control during the duration of the study therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Signed, institutional review board (IRB) approved written informed consent
You may not be if
Concurrent invasive malignancy, not including:
1. Non-melanomatous skin cancer
2. In situ malignancies
3. Concurrent superficial endometrial carcinoma, if their endometrial carcinoma is superficial or invades less than 50% the thickness of the myometrium)
4. Low risk breast cancer (localized, non-inflammatory) treated with curative intent
Lesions identifiable only by positron emission tomography (PET)
Prior treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, including BSI-201
Major medical conditions that might affect study participation (i.e., uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection)
Other significant co-morbid condition which the investigator feels might compromise effective and safe participation in the study, including a history of congestive cardiac failure or an electrocardiogram (ECG) suggesting significant conduction defect or myocardial ischemia
Enrollment in another investigational device or drug study, or current treatment with other investigational agents
Concurrent radiation therapy to treat primary disease throughout the course of the study
Inability to comply with the requirements of the study
Pregnancy or lactation
Leptomeningeal disease or brain metastases requiring steroids or other therapeutic intervention
